

## **FOR IMMEDIATE RELEASE**

### ***Chain Drug Stores Welcome CliniDATA Source at NACDS***

August 22, 2001. Irvine, CA — CliniDATA Source, a subsidiary of Etreby Computer Company, recently made its debut at the National Association for Chain Drug Stores (NACDS) conference in Chicago. The meeting's theme, "Pharmacy & Technology", provided the perfect environment for chain drug stores to evaluate CliniDATA Source as a new technology option for clinical information and drug pricing. The database is already in use in over 2,000 independent retail pharmacies worldwide.

At the conference, CliniDATA Source staff met with major pharmacy chains in back-to-back meetings.

"For many, this was the first time they had heard of CliniDATA Source. The response was incredibly positive. Every company was pleased to learn that they now have a choice, that a highly respected clinical systems developer is now offering an alternative for accurate, up-to-date clinical information and drug pricing," said Trish Salazar, product sales representative.

In January 1998, the Hearst Corporation, parent company of First Databank Inc., acquired Medi-Span, Inc. Since then, the price for First Databank's database has more than tripled, leaving customers with few options.

#### **About CliniDATA Source**

CliniDATA Source provides clinical information and drug pricing data to pharmacies worldwide. CliniDATA Source's dose checker, interaction database and patient information handouts help prevent medication errors every day. The company has been in business since January of 2000 and is a subsidiary of Etreby Computer Systems, a healthcare software development company that has been providing systems solutions to pharmacies for over 20 years. CliniDATA Source is currently offered as an option by seven pharmacy software vendors.

#### Contact:

Trish Salazar, Product Manager  
800-238-7329 Ext. 480  
[TSalazar@etreby.com](mailto:TSalazar@etreby.com)  
[www.CliniDATASource.com](http://www.CliniDATASource.com)

This release contains certain "forward-looking statements," relating to the Company's business, which can be identified by the use of forward-looking terminology such as "may," "promising," or similar expressions, or by discussions of strategy, plans or intentions. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Any such commercialization can be affected by, among other things, uncertainties relating to product development, regulatory actions or delays or government regulation generally, the ability to obtain or maintain patent or other proprietary intellectual property protection, lack of pharmaceutical companies to provide pricing information, competition in general and other risks and factors referred to in Form 20-F of the Securities and Exchange Commission of the United States.